Using high *effective risk* of Adult-Senior duo in multigenerational homes to prioritize COVID-19 vaccination

Brijesh Saraswat[1], Santosh Ansumali[1,2]* and Meher K. Prakash[1,3]

[1]*Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064*
[2]*Sankhya Sutra Labs, Manyata Embassy Business Park, Bengaluru, Karnataka, India 560045*
[3]*VNIR Biotechnologies Pvt Ltd, Bangalore Bioinnovation Centre, Helix Biotech Park, Electronic City Phase I, Bangalore 560100*

Corresponding Author: ansumali@jncasr.ac.in

—

Abstract

Immediate and universal vaccination is a way of controlling the COVID-19 infections and deaths. Shortages of vaccine supplies and practical deployment rates on the field necessitate prioritization. The *global* strategy has been to prioritize those with a high personal risk due to their age or comorbidities and those who constitute the essential workforce of the society. Rather than a systematic age-based roll-down, assigning the next priority requires a *local* strategy based on the vaccine availability, the effectiveness of this specific vaccine, the population size as well as its age-demographics, the scenario of how the pandemic is likely to develop. The Adult (ages 20-60) – Senior (ages over 60) duo from a multigenerational home presents a high-risk demographic, with an estimated "effective age" of an adult to be 40 years more if they live with an unvaccinated grandparent. Our model suggests that strategically vaccinating the Adults from multigenerational homes in India may be effective in saving the lives of around 70,000 to 200,000 of Seniors, under the different epidemiological scenarios possible with or without strict lockdowns.

Introduction

COVID-19 pandemic management required the use of Non-Pharmaceutical Interventions (NPIs) including severe full or graded lockdowns [Ferguson *et al.* 2020]. The nearly 3 million deaths caused by COVID-19 are much lesser than the counterfactual scenario with no interventions. Although herd-immunity through infection was seen as an option, the unprecedented scale of deaths argued against it [Randolph *et al.* 2020; Fontanet *et al.* 2020]. Thus the NPIs continue to play a critical role of flattening the infection curve [Anderson *et al.* 2020].

The only way of ending the pandemic, and to come out of the cycle of graded lockdowns is immediate and universal vaccination. Commensurate with the scale of pandemic, several vaccines have been developed and became available at an accelerated speed [Corum *et al.* 2020; Forni *et al.* 2021; Voysey *et al.* 2020]. These vaccines have demonstrated an effectiveness ranging from 60% to 95% [Forni *et al.* 2021]. Although these vaccines are available and effective in principle, there are several challenges in their deployment. The vaccines based on mRNA technology require a cold-chain of -80°C, while most others with easier cold-chain requirements have lower effectiveness. More importantly, all of these vaccines are with a production and supply [Mills and Salisbury, 2020; Irwin 2021] that is limited compared to the immediate global need.

Considering these challenges, the taskforces across the world have recommended prioritized vaccination of the vulnerable [NASEM, 2020]. The principal factor guiding the recommendations is the mortality risk posed by age (over 60 years) and comorbidities. The first priority group also included health care workers and other essential work force of the society, who although may not be at the risk of death, cannot be quarantined due to infections without crippling the functional society. The choice of the vulnerable and the essential for the first priority was almost universally adopted by all the governments.

However, the next phase prioritization strategy is not clear. At the rate of current vaccination, it is feared that most countries, may need at least another year in the ideal scenario without any manufacturing or distribution delays. A systematic roll-down across the different age groups is not a practical strategy for many countries, especially if they have a large young population, such as in India. The 'pyramid' structure of the age demographics in the population, where the population increases in the younger age brackets, presents more candidates to be vaccinated in each roll-down phase. Paradoxically, the younger population which is larger in number also has a lower mortality risk [Levin et al. 2020; Ghisolfi *et al.* 2020], which requires a re-examination of the vaccination strategy beyond those covered in the first priority.

Since the per-capita availability of vaccines in USA has not been a challenge, and most European countries are still vaccinating the vulnerable in the first priority, it appears that the grey area that is faced by India today on "Who is next?", did not receive sufficient attention in our opinion. This may be a question that the European countries may be confronted with as soon as the first priority group is vaccinated.

Vaccinating the family members of the vulnerable is a well-known strategy when the vaccine is considered not so safe or if the vulnerable have a lower immunity levels due to HIV or other factors which prevents them from developing antibodies [Public Health England, 29 March 2021]. However, since all the vaccine manufacturers sufficiently demonstrated safety, the discussion of vaccinating the family members of the vulnerable did not take prime importance.

In this work, we systematically evaluate and demonstrate the effectiveness of this strategy of vaccinating the young family members from the multigenerational homes on a priority basis in the Indian context, by combining it with the local realities of vaccination availability, effectiveness as well as the developing epidemiological scenario.

Results and Discussion.
Indian COVID-19 and vaccination scenario.
The vaccination strategy should consider the three *local* realities of the society for which the analysis is meant: Vaccine availability, COVID-19 incidence, age-demographics.

Vaccine availability. The two types of vaccine readily available in India are from the COVISHIELD (Serum Institute of India-AstraZeneca Plc) [Voysey *et al.* 2020] and COVAXIN (Bharat Biotech Intl. Ltd.) [Ella *et al.* 2021]. Both of these vaccines are proven for their safety. The former has shown an effectiveness of 67% in reducing infections, 70% in reducing the transmission [Voysey *et al.* 2021], and we assume the same for the latter. We further assume a 80% reduction in mortality death due to vaccination, across all ages [Bernal *et al.* 2021; Public Health England 01 March 2021]. The combined production capability of these two vaccines is around 60 million doses monthly. A step-up in production is expected between July to September 2021, but we present our model based on the present situation.

COVID-19 incidence. Flu-like infections spread rapidly in winter. In the winter of 2020, India was in an 'unlock' phase with minimal NPIs, and yet COVID-19 infections were contained. Several hypotheses surrounded this observation - including protection from previous infectious diseases, herd immunity with a large unmonitored COVID-19 infection. However, in the spring of 2021, the second wave of COVID-19 started, with case-loads exceeding 150,000 daily infections (*https://www.covid19india.org*). The rising pattern appears to parallel the rise of infections in the spring and summer of 2020. If this situation continues, either because there is an inherent spread of infection under hot conditions due to climatization [Sruthi *et al.* 2021] or any other reasons, one may expect rising infections until September 2021. Studying the second-wave from the countries [Worldometers, 2020] which had the most infections (**Supplementary Table 1**), it is clear that all of them had a peak of the second wave that was worse than the first wave of the spring of 2020 (ratio: 4.35±1.95). Several factors may have contributed to this large second peak, including the need to keep the economy active as well as a confidence in a better management of critical cases through effective treatment.

Further, the *full-width at half-maximum* (a model-free way of defining the width) for the duration of the second wave in most COVID-19 affected countries lasted 27 to 122 days, with extreme and moderate restrictive NPIs respectively. This duration is also commensurate with the width of half-maximum (108 days) of the first wave of COVID-19 infections which occurred in the same season in 2020. While we acknowledge that it is hard to predict whether the actual trends in infections which may be checked by several unknowns such as attainment of herd-immunity, or imposition different grades of lockdowns, the global trends in the peak and the width of the second-wave serve as a guideline for estimating the consequences under some realistic worst-case scenarios (**Population Level Model** below).

Age demographics. The age-binned population data was obtained from the 2011 census. To estimate the population distribution in 2021, the population in each bin was multiplied by 1.125 to match the overall 12.5% increase in the Indian population between 2011-2021. Clearly the population is largely young: 553 million (ages 0-20), 527 million (20-45), 173 million (45-60), 119 million (60+), with a low individual risk and requires multiple layers of prioritization.

Effective Risk and Effective Age.

Age and the presence of comorbidities are risk factors for COVID-19 fatality [Levin et al. 2020; Ghisolfi et al. 2020]. The risk profile of an individual is defined by the infection fatality rate (IFR), which quantifies the chance of death when a person of a given demographic is infected by COVID-19. Defining an adult living in a multigenerational home as a new demographic allows us to obtain an "effective" risk profile for this group. The chance of death in this Adult-Senior duo, due to a COVID-19 infection in the Adult, is the chance of fatality in the Adult, combined with the chance of fatality in the Senior weighted by the chance of Secondary Attack (transmission) at home:

Effective Risk(*adult*) = IFR(*adult*) + Secondary Attack Rate *
Chance of infection of a vaccinated or unvaccinated Senior *
Mortality risk of a vaccinated or an unvaccinated Senior

We used the infection fatality rate data (**Supplementary Table 2**) from Levin *et al.* 2020 to calculate the effective risk and to estimate the effective age (**Table 1**). **Table 1** utilizes the home contact structure for India with an approximate 25 year intergenerational gap, and the effectiveness of the COVISHIELD (*Serum Institute of India – AstraZeneca Plc*) vaccines that is mostly used in India. It is clear that the "effective age" of an Adult in a multi-generational home is 15 years more if living with an unvaccinated parent (Senior) or 40 years more if living with an unvaccinated grandparent (Senior). This personal risk quantification suggests the need for estimating the advantages of preferential vaccination of Adults from multigenerational homes as a public health strategy, under the different epidemiological scenarios.

Population level Model.

Focus. The focus of the work is on how vaccination of the "Adults" (ages 20 to 60) reduces the secondary infections and deaths among the "Seniors" (ages 60 and above). The deaths among the Adults, and the deaths among Seniors who are infected by means other than through families are *not* reported.

Contact structure. The home-contact matrix for India [Prem *et al.* 2017] shows a banded structure with a contact between same age group, and those with differences of 25 and 50 years, suggesting an underlying generational gap of 25 years. We assume each Senior of age S is related to one child of age (S-25) and one grandchild of age (S-50). Since the focus is on intergenerational infections, this assignment is performed only if the age of the child or the grandchild is <60.

Overall incidence. We consider four different scenarios of the development of COVID-19 second wave in India. The number of daily infections crossed 150,000 by 12 April 2021. We consider a conservative scenario of

infections reaching a peak of 225,000 with a flattening for month and a subsequent decrease. In all other scenarios we considered a peak daily infection of 400,000, commensurate with the average ratio of the peak in the second versus the first waves in the top COVID-19 affected countries. These observations from the most affected countries (**Supplementary Table 1**) guided us to assume the four different epidemiological scenarios shown graphically in **Figure 2A**. The total number of daily infections are assumed to be distributed in the population in the ratio of the susceptible population in each group.

Secondary attack rate. The secondary attack due to an infection in family is around 30% [Madewell *et al.*, 2020].

Effect of vaccination. The effect of vaccination is assumed mainly based on the data from AstraZeneca reports – the chance of infection is reduced by 67%, transmission by 70%, and mortality among the infected by 80%. We assume that the these reductions are universally applicable to all age groups, and regardless of the vaccine type.

Other model assumptions. The many existing and possible new variants not considered to be different, for age-dependent fatality or for the effectiveness of the vaccine. At least in the 6 month period, a person who is infected with COVID-19, is assumed not to be reinfected. The potential deaths in Seniors are assigned to the day on which an adult is infected for simplicity of the analysis, although the same analysis may equally be presented with a time delay including hospitalization times. The vaccination rates may increase slightly, this increase may be compensated by the need for the second dose. Thus, to not invoke complicated scenarios of vaccine availability, hesitancy, second dose delays, we perform the analysis believing the 1st dose of the vaccine implicitly delivers its effectiveness.

A   **B**

Figure 1. Intergenerational contact structure. A. Age-structured home contact network in India, obtained from Prem *et al.* 2017. The figure shows a clear banded structure, with a 25 year intergenerational time. **B.** The inferred intra home contact network that was used in this work. The model assigns to every Senior of age *S>60*, a first generation home contact of *S-25* and a second generation home contact of *S-50*, as long as these contacts have an age of less than 60.

Impact of prioritizing adults in a multigenerational home

By 12 April 2021, as shown in **Supplementary Table 3**, the priority vaccination for Seniors had a coverage of around 50%, and about 20% from the second priority group of ages 45-60 have been vaccinated [*https://dashboard.cowin.gov.in/*]. Under the four scenarios of COVID-19 second wave development (**Figure 2A**), we studied the effectiveness of vaccinating with two different strategies – age based roll-down to younger populations, and a preferential targeted vaccination of younger members from multigenerational homes. By adopting a targeted strategy, the susceptible Adults from multigenerational families may all be vaccinated in a relatively short time of 52 days if administered at 2 million doses per day, compared to a uniform age-based strategy (**Figure 2B**). In most realistic scenarios, the number of deaths among the

Seniors due to transmissions from the adults in the family (**Table 1**) are likely to be reduced by over 100,000 due to this targeted strategy.

Age of an unvaccinated adult	If with a vaccinated grandparent		If with an *unvaccinated* grandparent		If with a vaccinated parent		If with an *unvaccinated* parent	
	Effective risk	**Effective age**	Effective risk	**Effective age**	Effective risk	**Effective age**	Effective risk	**Effective age**
20	0.05392	35	0.7984	60	0.00874	20	0.0454	35
25	0.09628	40	1.4245	65	0.01546	25	0.0775	40
30	0.16634	45	2.459	70	0.02756	30	0.146	45
35	0.31864	50	4.684	75	0.05386	35	0.271	52
40	0.56716	55	8.356	80	0.09574	42	0.499	56
45	0.62716	55	8.416	80	0.17752	48	0.922	62
50	0.71716	60	8.506	80	0.30478	53	1.633	67
55	-	-	8.506	-	0.56634	57	2.859	71

Table 1. Effective Age. The "effective risk" for each adult in the age 20-55 living in a multigenerational home, is defined based on the COVISHIELD (AstraZeneca) effectiveness and a 25 year intergenerational gap. The age-dependent infection fatality rate shown in **Supplementary Table 2** was obtained from Levin *et al.* 2020. The "effective age" was obtained by a reverse-lookup of the risk from the **Supplementary Table 2**. Considering the goal of reducing COVID-19 related deaths, an adult living with an unvaccinated parent or grandparent is effectively older by 15 years or 40 years respectively.

Figure 2. COVID-19 development scenarios and deaths avoided. A. The four COVID-19 development scenarios considered in this study. Scenario 1 is the most conservative scenario considering the daily infections on 12 April 2021. The peak of daily infections in all other scenarios is assumed to be 400,000 and is based on the average ratio of second to first peak observed in countries with the most infections (**Supplementary Table 1**). **B.** Comparison of two strategies based on (top) no-selectivity in vaccinating members of multigenerational families and (bottom) preferential vaccination to younger members of multigenerational families for scenario 3. The deaths reduced among the Seniors by vaccinating the adults in all four scenarios is shown in **Table 2**.

Pattern of daily new infections for 180 days	Deaths among Seniors due to transmission from adults. Vaccinating 2 million/day		Deaths among Seniors due to transmission from adults Vaccinating 3 million/day	
	Uniform vaccination	Targeted vaccination of Adults (20-60)	Uniform vaccination	Targeted vaccination of Adults (20-60)
Scenario 1	189,652	85,513	187,901	54,871
Scenario 2	183,443	109,663	182,510	75,077
Scenario 3	343,988	119,905	333,952	76,732
Scenario 4	363,405	102,709	350,929	60,460

Table 2. Reduction of deaths among Seniors. The two different vaccination strategies employed have varying impacts on the transmission of infections from adults to Seniors, and the consequent deaths among Seniors. The results from the model are shown under the different pandemic scenarios. Also, while we assume the age-dependent mortality rate obtained from the meta-analysis of Levin *et al*. 2020. The lives saved are also considerably high even if the mortality rates may be 20% lesser in the second wave in India, due to better therapeutic management or other reasons.

Possible immediate strategy for prioritization in India.

The vaccination drive in India is very active, and ranks very high globally in absolute numbers (132 million doses administered as of 12 April 2021). Although 41 million Seniors and 91 million Adults have been vaccinated, there are still large gaps in coverage (**Supplementary Table 3**). Delhi has a vaccination coverage of 53% among the Seniors. The coverage among Seniors varied widely across the states with a mean and standard deviation of 42% and 21%, respectively. We ask if vaccinating the vulnerable, and those next to them, is easily achievable with the available resources. The number of vaccines required to completely vaccinate the Seniors is around 77 million more. Similarly, from our estimates based on the family structure model we described, the number of adults from multigenerational homes that need to be vaccinated is 144 million more. It is quite possible that the vaccine hesitancy in India is low, as one of the largest states Rajasthan shows a vaccination coverage of 78% among the Seniors. Thus, with the stock of vaccinations India has, it is feasible to vaccinate almost all of these high risk and high 'effective risk' populations within 2 to 3 months. The strategy can be further refined and made granular by recognizing that the pandemic spread is not uniform across the country, and the case load migrates [Ansumali *et al*. 2020]. It is also possible to preferentially vaccinate these populations with high risk and 'high effective risk' in districts or states that are at the highest risk of COVID-19 infections.

Using *Effective risk* for public health strategy when individual risk is low.

Vaccinating the family members of the vulnerable is a well-known strategy to break the transmission chain leading up to the vulnerable. This is especially recommended if the vaccine is not safe for the vulnerable or if they are not likely to develop antibodies due to a compromised immune system. Multigenerational homes have been believed to be the major factor behind the high COVID-19 casualties in many countries, Italy for example. Whereas in the vaccination strategies of USA [NASEM, 2020], the considerations of the multigenerational homes have been important mainly to identify the vulnerable ones outside the long-term care facilities. The Swiss task force explicitly prioritized "close contacts", household members or relatives providing care to people at risk, in priority group 3. However, the rationale, the age groups which qualify and comparison between individuals of middle-age versus those who are younger but living with older members could not be gathered easily from the public domain. Further, to the best of our knowledge, public health strategies weighing the epidemiological scenarios against the vaccine availability [Bubar *et al*. 2021], have not evaluated the societal impact of vaccinating the family members of the vulnerable, considering the *local* realities of the family structure, secondary attack rates, and the effectiveness of the available vaccines. We devise the strategy based on the "effective risk" and quantify its effectiveness using our model-based analysis.

Defining and formalizing an "effective risk" or "effective age" among people of low individual risk, using their familial, social, or work-related interactions is more general than the intergenerational risk studied here, and can be customized in principle for the *local* conditions of any country.

Conclusions.

While successfully conducting large-scale vaccination drives, India faces the challenge of vaccinating a large young population. The "effective age" of an unvaccinated adult living with a grandparent we define by combining their risks, may be even 40 years more, thus underscoring the need to vaccinate those living with the vulnerable. By placing this risk through the Adults in the family, in the context of current vaccination rates, it is possible to prioritize and administer the vaccinations to the Seniors, and Adults who are in multigenerational homes, there by significantly reducing the chances of deaths in epidemiological scenarios where the second wave may last for an additional 3 to 6 months.

Acknowledgements.

SA and MKP thank Dr. Aloke Kumar for helpful discussions.

Author contributions.

SA and MKP conceptualized the project; BS and MKP performed calculations; SA and MKP wrote the article.

References

Anderson, Roy M., et al. "How will country-based mitigation measures influence the course of the COVID-19 epidemic?." *The lancet* 395.10228 (2020): 931-934.

Ansumali, Santosh, et al. "A steady trickle-down from metro districts and improving epidemic-parameters characterize the increasing COVID-19 cases in India." *Available at SSRN 3701553* (2020)

Bernal JL, Andrews N, Gower C et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England, *medRxiv.* 2021; https://doi.org/10.1101/2021.03.01.21252652

Bubar, Kate M., et al. "Model-informed COVID-19 vaccine prioritization strategies by age and serostatus." *Science* 371.6532 (2021): 916-921.

Corum, Jonathan, et al. "Coronavirus vaccine tracker." *The New York Times* 5 (2020).

Ella, Raches, et al. "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial." *The Lancet Infectious Diseases* (2021).

Ferguson, Neil, et al. "Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand." *Imperial College London* 10.77482 (2020): 491-497.

Fontanet, Arnaud, and Simon Cauchemez. "COVID-19 herd immunity: where are we?." *Nature Reviews Immunology* 20.10 (2020): 583-584.

Forni, Guido, and Alberto Mantovani. "COVID-19 vaccines: where we stand and challenges ahead." *Cell Death & Differentiation* 28.2 (2021): 626-639.

Ghisolfi, Selene, et al. "Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity." *BMJ global health* 5.9 (2020): e003094

Irwin, Aisling. "What it will take to vaccinate the world against COVID-19." *Nature* (2021)

Levin, Andrew T., et al. "Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications." *European journal of epidemiology* (2020): 1-16.

Madewell, Zachary J., et al. "Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis." *JAMA network open* 3.12 (2020): e2031756-e2031756.

Mills, Melinda C., and David Salisbury. "The challenges of distributing COVID-19 vaccinations." *EClinicalMedicine* 31 (2021).

National Academies of Sciences, Engineering, and Medicine. "Framework for equitable allocation of COVID-19 vaccine." (2020).

Prem, Kiesha, Alex R. Cook, and Mark Jit. "Projecting social contact matrices in 152 countries using contact surveys and demographic data." *PLoS computational biology* 13.9 (2017): e1005697.

Public Health England, New data show vaccines reduce severe COVID-19 in older adults, 1 March 2021, https://www.gov.uk/government/news/new-data-show-vaccines-reduce-severe-covid-19-in-older-adults

Public Health England, JCVI recommends that adults living with adults who are immunosuppressed should be prioritised for the COVID-19 vaccine, 29 March 2021, https://www.gov.uk/government/news/new-vaccine-advice-for-adults-living-with-adults-who-are-immunosuppressed

Randolph, Haley E., and Luis B. Barreiro. "Herd immunity: understanding COVID-19." *Immunity* 52.5 (2020): 737-741.

Sruthi, C. K., et al. "Estimating Effect-sizes to Infer if COVID-19 transmission rates were low because of Masks, Heat or High because of Air-conditioners, Tests." *medRxiv* (2021).

Voysey, Merryn, et al. "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials." *The Lancet* 397.10277 (2021): 881-891.

Voysey, Merryn, et al. "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK." *The Lancet* 397.10269 (2021): 99-111.

Worldometer. "COVID-19 pandemic." (2020), accessed from https://www.worldometers.info/coronavirus/#countries

Supplementary Information

Country	Peak daily infections			Active infections at peak			2nd Peak width	
	First wave	Second wave	Second wave/first wave	First wave	Second wave	Second wave/first wave	Width at half peak height (days)	Degree of restriction
USA	35278	76,268	2.16	1127293	2444516	2.16	77	Moderate
Brazil	46263	77129	1.66	818533	1293839	1.58	>103 (ongoing)	Low
France	4852	56377	11.62	59336	1962739	33.08	28	Strict
Russia	10982	28616	2.60	245580	563754	2.29	122	Low
UK	4513	25283	5.60	193327	1013141	5.24	38	Strict
Turkey	12400	31787	2.56	86675	224245	2.58	37	Strict
Italy	6,554	41,195	6.28	108077	803591	7.43	44	Strict
Spain	8641	20169	2.33	138061	542985	3.93	47	Strict
Germany	5837	25441	4.36	72865	400245	5.49	91	Moderate

Supplementary Table 1. The 95% confidence interval for the ratio of the 2nd peak to the 1st peak is this 4.3522 $\pm$1.954. Similarly, the active case ratio between the second and the first waves is 3.8375 $\pm$1.331 excluding the outlier France (and 7.0867 $\pm$6.12 if include France). COVID-19 incidence data was obtained from *https://worldometers.info*

Age	20	25	30	35	40	45	50	55	60	65	70	75	80	85	90	95	100
Mortality risk	0.0064	0.0115	0.02	0.04	0.07	0.13	0.22	0.42	0.77	1.43	2.64	4.71	8.13	15.48	27.62	27.62	27.62

Supplementary Table 2. Age-dependent infection fatality risk obtained from Levin *et al.* 2020 was used in our analysis. This data was also used for a "reverse-lookup" of effective age when the effective risk was computed.

	Seniors (age 60+)		Estimated adults (ages 20-60) in Family	
State	**Vaccinated**	**Still needing vaccines**	**Vaccinated**	**Still needing vaccine**
Andaman and Nicobar	10,818	17,784	3,382	34,659
Andhra Pradesh	1,331,327	4,157,514	490,817	7,300,159
Arunachal Pradesh	22,490	49,104	10,831	84,389
Assam	427,893	1,910,469	143,789	2,966,232
Bihar	2,226,271	6,444,267	458,751	11,073,065
Chandigarh	41,381	34,082	8,638	91,728
Chattisgarh	1,438,098	816,300	520,177	2,478,172
Dadra and Nagar Haweli	6,531	9,098	2,497	18,290
Daman and Diu	10,311	2,470	2,094	14,905
Delhi	695,327	595,549	181,430	1,535,435
Goa	75,917	108,015	18,413	226,217
Gujarat	3,525,625	1,859,254	929,160	6,232,729
Haryana	1,154,937	1,313,038	240,115	3,042,292
Himachal Pradesh	453,561	337,324	112,291	939,586
Jammu and Kashmir	444,115	593,873	140,655	1,198,453
Jharkhand	967,958	1,683,305	225,656	3,300,524
Karnataka	2,725,660	3,789,251	684,709	7,980,123
Kerala	2,565,167	2,152,400	550,710	5,723,654
Ladakh	23,859	6,141	8,349	33,067
Lakshadweep	3,358	2,571	1,410	6,476
Madhya Pradesh	2,433,448	3,994,033	624,500	7,924,050
Maharashtra	4,203,234	8,292,068	1,253,221	15,365,531
Manipur	3,813	221,210	15,477	283,804
Meghalaya	26,220	130,045	11,146	196,686
Mizoram	25,377	51,830	8,061	94,624
Nagaland	19,121	96,446	8,867	144,837
Odisha	1,894,449	2,588,055	449,739	5,511,991
Puducherry	32,121	103,370	14,630	165,573
Punjab	696,442	2,527,602	261,600	4,026,379
Rajasthan	4,497,085	1,254,071	873,591	6,775,446
Sikkim	38,018	7,828	10,643	50,332
Tamil Nadu	1,237,026	7,211,452	510,430	10,726,046
Telangana	739,704	1,653,896	277,492	4,795,500
Tripura	247,641	78,096	92,798	340,432
Uttar Pradesh	3,380,058	13,989,835	995,726	22,106,232
Uttarakhand	539,872	473,538	147,081	1,200,754
West Bengal	3,185,711	5,524,469	810,169	10,774,370

Supplementary Table 3. Vaccine coverage and needs. State wide vaccine coverage and needs among the Seniors (over 60 years) and the adults (20-60) estimated to be in multigenerational homes with a direct contact with the Seniors. Vaccination statistics are obtained from the Indian Government portal https://dashboard.cowin.gov.in/